Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2441-2460 of 3,900 trials

Locally Advanced Rectal Cancer: CApecitabine and Temozolomide Study

We are studying a new treatment combining capecitabine and temozolomide for patients with specific types of locally advanced rectal cancer. The goal is to see if this combination improves tumor response and surgical outcomes.

Locally Advanced Rectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Flu Vaccine Study: LAIV in Young Children

We are studying how the LAIV flu vaccine affects the immune response in young children. This research aims to see how well it protects against flu and influences overall health.

Influenza≤3 monthsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPediatricsPulmonology

Metastatic Breast Cancer: Next Generation Sequencing Oncochip

We are studying a new sequencing tool to help decide the best treatment for metastatic breast cancer patients. The goal is to see if it improves survival and response compared to standard chemotherapy.

Breast Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

HIV Treatment: IMC-M113V Study

We are evaluating a new treatment, IMC-M113V, for people with chronic HIV infection who are already on medication. The study will help us understand its safety and how it affects the immune system.

Chronic HIV Infection3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementInfectious DiseasesInternal Medicine

New Treatment for Limbal Stem Cell Deficiency: Oral Mucosa Cells

We are testing a new method using cultured cells from the mouth to help people with limbal stem cell deficiency. This study aims to see if this treatment can improve eye health and vision.

Limbal Stem Cell Deficiency>2 yearsSafety phase (I)Efficacy phase (II)Ophthalmology

Hepatocellular Carcinoma: Durvalumab and Tremelimumab with Y-90 SIRT

We are studying a combination of immunotherapy and radiation therapy for patients with intermediate stage liver cancer who cannot have surgery. The goal is to see if this treatment can help shrink tumors and improve survival.

Non-resectable Hepatocellular Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteHepatologyOncology

Advanced Breast Cancer: Capivasertib and Fulvestrant Study

We are researching the combination of capivasertib and fulvestrant for patients with HR+/HER2- advanced breast cancer who have not responded to standard treatments. The study aims to evaluate treatment effectiveness and safety in real-world clinical practice.

Advanced Breast Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

TBR1-Related Neurocognitive Disorder: Lithium Carbonate Study

We are studying whether lithium carbonate can improve behavior and communication in patients with TBR1-related neurocognitive disorder. This trial will also assess the treatment's safety and overall impact on quality of life.

TBR1 Variant>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteNeurologyPsychiatry

Semaglutide for Obesity and Resistant Hypertension

We are exploring whether semaglutide can help people with obesity and resistant hypertension better control their blood pressure compared to a placebo. This study aims to assess if this approach is feasible.

Resistant HypertensionObesity6-12 monthsConfirmation phase (III)Standard MedicinesCost ReimbursementPartially RemoteCardiologyEndocrinologyInternal Medicine

Relapsing-Remitting Multiple Sclerosis: Ozanimod Study

We are studying how ozanimod may help limit brain changes in people with relapsing-remitting multiple sclerosis. The trial looks at its effects on disease activity, cognition, fatigue, and quality of life.

Multiple Sclerosis>2 yearsMonitoring phase (IV)Neurology

HPV Infections: 2LPAPI® Treatment Study

We are testing a new treatment, 2LPAPI®, for people with high-risk HPV infections to see if it helps clear the virus better than a placebo. The study also looks at safety and how the treatment affects cervical cell health.

Human Papillomavirus Infection>2 yearsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessStandard MedicinesGynecology and ObstetricsInfectious Diseases

Heart Failure and Kidney Disease: SENEKA Study

We are exploring a new treatment strategy for elderly patients with heart failure and chronic kidney disease to see if it helps manage potassium levels better. This study compares a potassium binder with standard medications to improve patient outcomes.

Chronic Heart Failure and Non-Dialysis Chronic Kidney Disease3-6 monthsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteCardiologyInternal MedicineNephrology

Sickle Cell Disease: CTX001 Treatment for Kids

We are studying a new gene-editing treatment for children with severe sickle cell disease. The trial aims to evaluate its safety and effectiveness in improving their health.

Sickle Cell Anaemia>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyPediatrics

Influenza Vaccination: Antibody Responses Study

We are investigating how intranasal and intramuscular flu vaccines affect antibody levels in the nose. This research may help improve future vaccination methods.

Healthy Participants≤3 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPulmonology

RAR-Immune: Nivolumab + Ipilimumab vs. Pazopanib for Advanced Sarcoma

We are studying whether a combination of nivolumab and ipilimumab works better than pazopanib alone for patients with advanced rare sarcomas. This trial will help us understand treatment effectiveness and patient quality of life.

Advanced Rare Sarcomas>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Diabetic Macular Edema: Fluocinolone vs. Dexamethasone Implants

We are comparing two eye implants to see which one better improves vision and is more cost-effective for patients with resistant diabetic macular edema. This study also looks at how these treatments affect quality of life.

Diabetic Macular Oedema>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementOphthalmology

GIST Treatment: Lenvatinib vs. Placebo

We are evaluating whether lenvatinib can help patients with advanced GIST who did not respond to imatinib and sunitinib. This study compares its effects to a placebo to assess its potential benefits.

Metastatic Gastrointestinal Stromal Tumor (GIST)>2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesOncology

Papillary Renal Cell Carcinoma: Axitinib with or without Pembrolizumab

We are studying the effects of axitinib alone versus axitinib combined with pembrolizumab in patients with advanced papillary renal cell carcinoma. This research aims to find out which treatment may work better as a first-line option.

Metastatic Renal Cell CarcinomaLocally Advanced or Metastatic Papillary Cell Carcinoma3-6 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncologyUrology

Pulmonary Hypertension: Mosliciguat Study

We are testing the medication Mosliciguat for individuals with pulmonary hypertension related to interstitial lung disease. The study aims to see if it helps improve heart function and walking ability.

Pulmonary Hypertension6-12 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPulmonology

Venous Thromboembolism in Cancer: Abelacimab vs. Dalteparin

We are studying whether a new medication, abelacimab, can effectively prevent blood clots in patients with gastrointestinal or genitourinary cancer. This trial compares it to the standard treatment, dalteparin.

Venous Thromboembolism (VTE)6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology